Merck Group, SpringWorks

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks
(This Feb. 10 story has been refiled to say 'LOEs (loss of exclusivity),' not 'LOEs (levels of evidence),' in paragraph 13) By Sabrina Valle and Patricia Weiss NEW YORK/FRANKFURT (Reuters) - Merck KGaA,
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics
Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks Therapeutics Inc (NASDAQ:SWTX), which has a market capitalization of $4.02 billion,
Merck KGaA in Talks to Buy SpringWorks Therapeutics
Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring.
Germany’s Merck in Talks to Buy SpringWorks Therapeutics
Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.
Exclusive-Germany's Merck KGaA in talks to buy US cancer biotech firm Springworks, sources say
Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics , according to people familiar with the matter.
Merck KGaA in advanced talks to acquire SpringWorks Therapeutics
KGaA said it is in advanced discussions regarding a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical firm specializing in rare diseases and cancer treatments.
SpringWorks Therapeutics jumps on report of Merck KGaA takeover talks
SpringWorks Therapeutics (NASDAQ:SWTX) soared 12% after a report that Merck KGaA (OTCPK:MKGAF) is in advanced discussions to acquire the cancer and rare disease drugmaker. If an agreement is reached,
US FDA approves SpringWorks' genetic disorder drug
The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLIâ„¢ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...
FiercePharma17h
UPDATE: Merck KGaA sets its sights on acquisition of Ogsiveo maker SpringWorks
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
FDA approves new genetic disorder drug
The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Springworks Therapeutics (SWTX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adaptive Biotechnologies (ADPT – Research ...
SpringWorks Stock Jumps More Than 30% on News of Possible Deal
SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.
pharmaphorum16h
Merck confirms its interest in buying SpringWorks
Merck said in a brief statement that discussions are "advanced" but noted that "critical conditions have yet to be met" ...
SpringWorks Therapeutics may be worth around $77 a share in a takeover - analyst
SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...
SpringWorks Therapeutics price target raised to $65 from $55 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $65 from $55 and keeps a Buy rating on the ...